负载裂解物成熟树突状细胞疫苗联合标准放化疗治疗新诊断胶质母细胞瘤的随机对照II期试验(GlioVax)研究方案
BACKGROUND: Despite the combination of surgical resection, radio- and chemotherapy, median survival of glioblastoma multiforme (GBM) patients only slightly increased in the last years. Disease recurrence is definite with no effective therapy existing after tumor removal.…
要点
- DC疫苗作为标准放化疗的附加治疗,可能改善新诊断GBM患者生存。
- 主要终点为OS,次要终点包括PFS、6/12/24个月生存率、安全性及生活质量。
- 随机分层因素为MGMT启动子甲基化状态,计划招募30个月、随访2年。
核心结论
- 需通过足够样本量的前瞻性随机II期试验明确DC疫苗对GBM患者PFS和OS的影响。
主要发现
- 既往近500例GBM患者在临床试验或同情用药中接受DC疫苗接种,结果令人鼓舞但缺乏稳健的临床疗效证据。
关键数值与推荐
- 主要终点为两组间总生存期(OS)比较;次要终点包括无进展生存期(PFS)、6、12、24个月OS和PFS率、安全性、总体及神经功能状态和生活质量。
临床怎么用
- DC疫苗作为标准放化疗的附加治疗,与标准治疗联合可能利用治疗模式间的协同作用。
局限性
- 既往DC疫苗研究为非对照或样本量小,无法提供稳健的临床疗效证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the combination of surgical resection, radio- and chemotherapy, median survival of glioblastoma multiforme (GBM) patients only slightly increased in the last years. Disease recurrence is definite with no effective therapy existing after tumor removal. Dendritic cell (DC) vaccination is a promising active immunotherapeutic approach. There is clear evidence that it is feasible, results in immunological anti-tumoral responses, and appears to be beneficial for survival and quality of life of GBM patients. Moreover, combining it with the standard therapy of GBM may allow exploiting synergies between the treatment modalities. In this randomized controlled trial, we seek to confirm these promising initial results. METHODS: One hundred and thirty-six newly diagnosed, isocitrate dehydrogenase wildtype GBM patients will be randomly allocated (1:1 ratio, stratified by O6-methylguanine-DNA-methyltransferase promotor methylation status) after near-complete resection in a multicenter, prospective phase II trial into two groups: (1) patients receiving the current therapeutic "gold standard" of radio/temozolomide chemotherapy and (2) patients receiving DC vaccination as an add-on to the standard therapy. A recruitment period of 30 months is anticipated; follow-up will be 2 years. The primary objective of the study is to compare overall survival (OS) between the two groups. Secondary objectives are comparing progression-free survival (PFS) and 6-, 12- and 24-month OS and PFS rates, the safety profile, overall and neurological performance and quality of life. DISCUSSION: Until now, close to 500 GBM patients have been treated with DC vaccination in clinical trials or on a compassionate-use basis. Results have been encouraging, but cannot provide robust evidence of clinical efficacy because studies have been non-controlled or patient numbers have been low. Therefore, a prospective, randomized phase II trial with a sufficiently large number of patients is now mandatory for clear evidence regarding the impact of DC vaccination on PFS and OS in GBM. TRIAL REGISTRATION: Protocol code: GlioVax, date of registration: 17. February 2017. Trial identifier: EudraCT-Number 2017-000304-14. German Registry for Clinical Studies, ID: DRKS00013248 (approved primary register in the WHO network) and at ClinicalTrials.gov , ID: NCT03395587 . Registered on 11 March 2017.
引用
- Rapp M, Grauer OM, Kamp M, et al. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial. Trials. 2018. PMID: 29801515. doi:10.1186/s13063-018-2659-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。